Released Nov 5, 2013, before the open
10-Q filed Nov 5, 2013, 36 days after period end · 0001104659-13-080831
Q3 2013 · 10-Q
Revenue—
Net income—
EPS Diluted-$0.27-$0.27 N/M vs Q3 2012N/M vs Q2 2013
Operating Income-$23,930,000N/M
Operating Cash Flowderived-$20,743,000N/M
Free Cash Flowderived-$20,871,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2013 | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|---|
| EPS Diluted | -$0.27 | -$0.36 | -$0.25 | $0.96 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR